Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 1
2013 1
2018 1
2019 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

6 results
Results by year
Filters applied: . Clear all
Page 1
Targeting oncogenic transcription factors by polyphenols: A novel approach for cancer therapy.
Rajagopal C, Lankadasari MB, Aranjani JM, Harikumar KB. Rajagopal C, et al. Pharmacol Res. 2018 Apr;130:273-291. doi: 10.1016/j.phrs.2017.12.034. Epub 2018 Jan 4. Pharmacol Res. 2018. PMID: 29305909 Review.
Inflammation is one of the major causative factor of cancer and chronic inflammation is involved in all the major steps of cancer initiation, progression metastasis and drug resistance. ...In this review we discuss the application of multi-targeting natural p …
Inflammation is one of the major causative factor of cancer and chronic inflammation is involved in all the major steps of cancer initiation …
Ketoconazole and the modulation of multidrug resistance-mediated transport in Caco-2 and MDCKII-MDR1 drug transport models.
Fan Y, Rodriguez-Proteau R. Fan Y, et al. Xenobiotica. 2008 Feb;38(2):107-29. doi: 10.1080/00498250701744625. Xenobiotica. 2008. PMID: 18197554
Cellular uptake of ketoconazole in the Caco-2 cells was significantly inhibited by CSA and digoxin, whereas epigallocatechin-3-gallate and xanthohumol exhibited biphasic responses. ...Epigallocatechin-3-gallate and xanthohumol modulate the transport and uptake of ke …
Cellular uptake of ketoconazole in the Caco-2 cells was significantly inhibited by CSA and digoxin, whereas epigallocatechin-3-gallate and …
Plant polyphenols and multidrug resistance: effects of dietary flavonoids on drug transporters in Caco-2 and MDCKII-MDR1 cell transport models.
Rodriguez-Proteau R, Mata JE, Miranda CL, Fan Y, Brown JJ, Buhler DR. Rodriguez-Proteau R, et al. Xenobiotica. 2006 Jan;36(1):41-58. doi: 10.1080/00498250500433545. Xenobiotica. 2006. PMID: 16507512
Xanthohumol significantly demonstrated (1) saturable efflux, (2) increased uptake of (3)H-digoxin and (3) decreased uptake of (3)H-CSA in the Caco-2 cells. The transport data suggests that xanthohumol effects transport of CSA in a manner that is distinct from the di
Xanthohumol significantly demonstrated (1) saturable efflux, (2) increased uptake of (3)H-digoxin and (3) decreased uptake of (3)H-CS
Inhibition of topoisomerase I activity and efflux drug transporters' expression by xanthohumol. from hops.
Lee SH, Kim HJ, Lee JS, Lee IS, Kang BY. Lee SH, et al. Arch Pharm Res. 2007 Nov;30(11):1435-9. doi: 10.1007/BF02977368. Arch Pharm Res. 2007. PMID: 18087812
Moreover, the expression of the drug efflux genes was investigated to predict the drug resistance. XN clearly decreased the mRNA levels of ABCB1 (MDR1), ABCC1 (MRP1), ABCC2 (MRP2), and ABCC3 (MRP3). These results suggest that XN has anticancer properties by i …
Moreover, the expression of the drug efflux genes was investigated to predict the drug resistance. XN clearly decreased …
The radio-sensitizing effect of xanthohumol is mediated by STAT3 and EGFR suppression in doxorubicin-resistant MCF-7 human breast cancer cells.
Kang Y, Park MA, Heo SW, Park SY, Kang KW, Park PH, Kim JA. Kang Y, et al. Biochim Biophys Acta. 2013 Mar;1830(3):2638-48. doi: 10.1016/j.bbagen.2012.12.005. Biochim Biophys Acta. 2013. PMID: 23246576
BACKGROUND: Chemotherapeutic drug resistance remains a clinical obstacle in cancer management. Drug-resistant cancer cells usually exhibit cross-resistance to ionizing radiation, which has devastating consequences for patients. ...Multi-drug
BACKGROUND: Chemotherapeutic drug resistance remains a clinical obstacle in cancer management. Drug-resistant cancer ce …
Xanthohumol, a Prenylated Flavonoid from Hops, Induces Caspase-Dependent Degradation of Oncoprotein BCR-ABL in K562 Cells.
Lu X, Geng J, Zhang J, Miao J, Liu M. Lu X, et al. Antioxidants (Basel). 2019 Sep 16;8(9):402. doi: 10.3390/antiox8090402. Antioxidants (Basel). 2019. PMID: 31527518 Free PMC article.
Tyrosine kinase inhibitors are the first choice for CML therapy, however, BCR-ABL mediated drug resistance limits its clinical application and prognosis. ...Antioxidant xanthohumol (XN) is a hop-derived prenylated flavonoid with multiple bioactivities. …
Tyrosine kinase inhibitors are the first choice for CML therapy, however, BCR-ABL mediated drug resistance limits its clinical …
Feedback